Expanded Access Programs
Expanded Access Programs
Search
Positive results reported in HER2 mutated lung cancer
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
FDA Approves Boehringer Ingelheim’s Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD
FDA Approves Boehringer Ingelheim’s Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD
Ruminants
Ruminants
Retinal Diseases
Retinal Diseases
Telemedicine – the standalone study that became the new normal
Dr Vijay Prabhakar tells us how a remote healing project made him a pandemic pioneer.Read it now!
The View from Both Sides of the Table
The View from Both Sides of the Table
Growing fresh produce for a cause at our U.S. headquarters
Growing fresh produce for a cause at our U.S. headquarters
Boehringer Ingelheim US Veterinary Scholars Program Profiles | Boehringer Ingelheim US
Click here to find out more how the Boehringer Ingelheim veterinary scholars program has helped 3,500 people over 30 years. Read five of their stories here.
Rising Star Leads with Determination | Boehringer Ingelheim US
Click to find out more on our partnership with the HBA, where we honor a BI colleague as a “Rising Star” to support the advancement of women in health care.
FDA Reaffirms Safety of Pradaxa® (dabigatran etexilate) | Boehringer Ingelheim US
An FDA study found that PRADAXA was associated with reduced risks of ischemic stroke, intracranial hemorrhage & death. View ISI, PI & Med Guide.
Supporting People with Diabetes and Related Conditions in the Time of COVID-19
Supporting People with Diabetes and Related Conditions in the Time of COVID-19
Ways we’re protecting the planet
Click here to read a few examples of the sustainability practices we’ve put in place at our U.S. HQ, to protect the planet for a more sustainable tomorrow.
Laura loves her diverse career
Laura loves her diverse career at Boehringer Ingelheim. For more talent insights, visit our Careers Page.
Corporate Profile
Corporate Profile
Coliform Mastitis: the facts to know | Boehringer Ingelheim US
Click here to learn more about different management practices that can help you to improve your dairy herd's bottom line and productivity.
Data Show Safety of Pradaxa® (dabigatran etexilate) in Children | Boehringer Ingelheim US
BI announces results from 2 pediatric studies of PRADAXA, presented at the ISTH Congress in Melbourne. View ISI, PI and Med Guide.
Corporate Compliance Program
Corporate Compliance Program
Pharmacy Rotations
Click here to read testimonies from our employees who enrolled in our pharmacy rotations academic program.
New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations
New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations
How Much Do You Know About PPID? | Boehringer Ingelheim US
Click here to find out more about some of the common misconceptions you might have about pituitary pars intermedia dysfunction (PPID).
Corporate Compliance Program
Our E&C Program conforms with the principles and recommendations published in guides from various Federal agencies and industry related organizations
What we do
Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
The Research Process
The Research Process
Vision & Values
Vision & Values